ArticleAnnals of the rheumatic diseases2006
Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment.
Article in Annals of the rheumatic diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 69 citations in OpenAlex.
- Targeting NF-κB and JAK/STAT pathways in rheumatoid arthritis: emerging nanocarrier-based drug delivery approaches.Inflammopharmacology · 2026Review
- Deciphering the Underlying Mechanisms Linking Psoriasis and IgA Nephropathy.Journal of immunology research · 2026Review
- Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment.Nature communications · 2025Article
- Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study.Journal of clinical medicine · 2024Article
- Diagnostic and prognostic role of synovial tissue analysis in juvenile idiopathic arthritis: a monocentric study.RMD open · 2023Article
- Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes.Frontiers in immunology · 2022Article
- Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.Arthritis research & therapy · 2021Article
- Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life.Journal of clinical medicine · 2020Article
- Article
- Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.Rheumatology (Oxford, England) · 2019Review
- Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.Scientific reports · 2018Article
- Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis.Arthritis research & therapy · 2017Article
- Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?Rheumatology international · 2016Review
- Anti-angiogenic effect of total saponins of RhizomaExperimental and therapeutic medicine · 2016Article
- Targeting of proangiogenic signalling pathways in chronic inflammation.Nature reviews. Rheumatology · 2016Review
- STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis.PloS one · 2016Article
- Synovial membrane protein expression differs between juvenile idiopathic arthritis subtypes in early disease.Arthritis research & therapy · 2014Article
- Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.Arthritis and rheumatism · 2012Article
- The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment.Arthritis and rheumatism · 2012Article
- Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia.Rheumatology international · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundModulation of Jak-STAT signalling may provide an effective therapeutic strategy in inflammatory arthritis (IA).
objectiveTo examine the effect of successful disease-modifying antirheumatic drug (DMARD) treatment on the expression of Jak-STAT in a cohort of patients with active rheumatoid arthritis.
methodsSynovial tissue biopsy specimens from 16 patients with active rheumatoid arthritis, taken before and after initiation of DMARD treatment, were examined for the presence of janus kinase (Jak)3, signal transducer and activator of transcription (STAT)1, STAT4 and STAT6 expression using immunohistochemistry.
resultsSuccessful treatment with DMARDs results in reduction in STAT1 expression in the lining, and STAT1 and STAT6 in the sublining of rheumatoid arthritis synovial tissue. Although the overall expression of STAT4 and Jak3 was not significantly altered by DMARD treatment, there was a significant reduction in the expression of the STAT4 and Jak3 bright cells, thought to be an activated dendritic cell subpopulation.
conclusionResults show that Jak3, STAT1, STAT4 expression and STAT6 sublining expression decrease in response to successful treatment of rheumatoid arthritis with standard DMARDs. Therefore, altering the expression of these pathways may represent an alternative treatment option, either through promoting up-regulation of inhibitory pathways, or suppressing inflammatory paths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.